| Published Application/Species/Sample/Dilution | Reference |
|---|
- western blot; mouse; fig 4b
- western blot; human; 1:1000; loading ...; fig 4a
| Li E, Huang X, Zhang G, Liang T. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res. 2021;40:279 pubmed publisher |
- immunohistochemistry; human; loading ...; fig 2d
| Strait A, Woolaver R, Hall S, Young C, Karam S, Jimeno A, et al. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma. Commun Biol. 2021;4:1005 pubmed publisher |
- western blot; human; loading ...; fig 6e
| Zhu Q, Ma Y, Liang J, Wei Z, Li M, Zhang Y, et al. AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6:299 pubmed publisher |
- immunocytochemistry; mouse; 1:50; fig 3k
- western blot; mouse; 1:1000; fig 1f, s3d
- western blot; human; 1:1000; loading ...; fig 1f
| Xu P, Xiong W, Lin Y, Fan L, Pan H, Li Y. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Cell Death Dis. 2021;12:779 pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 5e
- western blot; human; 1:1000; loading ...; fig 4a, 4c
| Mao C, Jiang S, Wang X, Tao S, Jiang B, Mao C, et al. BCAR1 plays critical roles in the formation and immunoevasion of invasive circulating tumor cells in lung adenocarcinoma. Int J Biol Sci. 2021;17:2461-2475 pubmed publisher |
- immunohistochemistry - paraffin section; human; 10 ug/ml; loading ...; fig 1e
| Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9: pubmed publisher |
- immunohistochemistry; human; 1:50; loading ...; fig 2a
| Pham Q, Taniyama D, Sekino Y, Akabane S, Babasaki T, Kobayashi G, et al. Clinicopathologic features of TDO2 overexpression in renal cell carcinoma. BMC Cancer. 2021;21:737 pubmed publisher |
- immunohistochemistry; human; loading ...; fig s7
| Lomphithak T, Akara Amornthum P, Murakami K, Hashimoto M, Usubuchi H, Iwabuchi E, et al. Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma. Sci Rep. 2021;11:11743 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1b
- western blot; human; 1:1000; loading ...; fig 4c
| Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, et al. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. Cancer Sci. 2021;112:3314-3323 pubmed publisher |
- western blot; human; loading ...; fig 1a, 2c, 2l
| Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, et al. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021;8:2003404 pubmed publisher |
- western blot; human; 1:2000; loading ...; fig 3b, 3d
| Gusyatiner O, Bady P, Pham M, Lei Y, Park J, Daniel R, et al. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma. Neuro Oncol. 2021;23:1680-1692 pubmed publisher |
- immunohistochemistry; human; 1:400; loading ...; fig 2c
| Morel K, Sheahan A, Burkhart D, Baca S, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021;2:444-456 pubmed publisher |
- immunohistochemistry; human; 1:400; loading ...
| Zhou J, Pei X, Yang Y, Wang Z, Gao W, Ye R, et al. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma. J Immunother Cancer. 2021;9: pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 2e
| Pezzuto F, Lunardi F, Vedovelli L, Fortarezza F, Urso L, Grosso F, et al. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment. Front Oncol. 2021;11:653497 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 5h
- western blot; human; 1:1000; loading ...; fig 2e, 3b, 4b
- western blot; mouse; 1:1000; loading ...; fig 2f, 7d
| Shang M, Yang H, Yang R, Chen T, Fu Y, Li Y, et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. Nat Commun. 2021;12:1940 pubmed publisher |
- immunohistochemistry; human; 1:50; loading ...
| Brune M, Stussi G, Lundberg P, Vela V, Heim D, Manz M, et al. Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol. 2021;100:1169-1179 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1e, 1f
- flow cytometry; human; loading ...; fig 3b
| Kuroki H, Anraku T, Kazama A, Shirono Y, Bilim V, Tomita Y. Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment. Oncol Lett. 2021;21:64 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3b, 3c
| Jiang X, Xu Y, Ren H, Jiang J, Wudu M, Wang Q, et al. KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity. Cell Biosci. 2020;10:139 pubmed publisher |
- western blot; human; 1:500; loading ...; fig 4n
| Banik S, Pedram K, Wisnovsky S, Ahn G, Riley N, Bertozzi C. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584:291-297 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:1000; loading ...; fig 6s1b
| Robbins Y, Greene S, Friedman J, Clavijo P, Van Waes C, Fabian K, et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. elife. 2020;9: pubmed publisher |
- western blot; human; loading ...; fig 6b
| Liao T, Lin C, Jiang J, Yang S, Teng H, Yang M. Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer. Theranostics. 2020;10:6095-6112 pubmed publisher |
- immunohistochemistry; human; loading ...
| Liu X, Kong W, Peterson C, McGrail D, Hoang A, Zhang X, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun. 2020;11:2135 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1d
| Kim M, Chung Y, Kim H, Woo J, Ahn S, Park S. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 5a
| Wu W, Jing D, Meng Z, Hu B, Zhong B, Deng X, et al. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics. 2020;10:2859-2871 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 3
| Mohme M, Maire C, Schliffke S, Joosse S, Alawi M, Matschke J, et al. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape. Acta Neuropathol Commun. 2020;8:28 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 3
| Herrera Rios D, Mughal S, Teuber Hanselmann S, Pierscianek D, Sucker A, Jansen P, et al. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. Front Immunol. 2020;11:120 pubmed publisher |
- immunocytochemistry; human; loading ...; fig 9c
- western blot; human; 1:1000; loading ...; fig 9b
| Asha K, Balfe N, Sharma Walia N. Concurrent Control of the Kaposi's Sarcoma-Associated Herpesvirus Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: a New Prospect for the Therapeutic Potential of Lipoxin A4. J Virol. 2020;94: pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; tbl 4
| Tsukagoshi M, Yokobori T, Yajima T, Maeno T, Shimizu K, Mogi A, et al. Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore). 2020;99:e19059 pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 4
| Sellier Y, Marliot F, Bessières B, Stirnemann J, Encha Razavi F, Guilleminot T, et al. Adaptive and Innate Immune Cells in Fetal Human Cytomegalovirus-Infected Brains. Microorganisms. 2020;8: pubmed publisher |
- immunohistochemistry - paraffin section; mouse; 1:1000; loading ...; fig 8i
| Orgaz J, Crosas Molist E, Sadok A, Perdrix Rosell A, Maiques O, Rodriguez Hernandez I, et al. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell. 2020;37:85-103.e9 pubmed publisher |
- immunocytochemistry; human; 1:100; loading ...; fig 6
- western blot; human; loading ...; fig 1a
| Verdura S, Cuyàs E, Cortada E, Brunet J, Lopez Bonet E, Martin Castillo B, et al. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging (Albany NY). 2020;12:8-34 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 3a
- western blot; human; loading ...; fig 4f, 6a
| Shima T, Shimoda M, Shigenobu T, Ohtsuka T, Nishimura T, Emoto K, et al. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma. Cancer Sci. 2020;111:727-738 pubmed publisher |
- western blot; human; loading ...; fig 2a
| Thiem A, Hesbacher S, Kneitz H, di Primio T, Heppt M, Hermanns H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38:397 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig s1b
| Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, et al. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. J Immunother Cancer. 2019;7:233 pubmed publisher |
- western blot; human; 1:1000; loading ...; fig 3a
| Wang S, Yao F, Lu X, Li Q, Su Z, Lee J, et al. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-1171 pubmed |
- immunohistochemistry; human; loading ...
| Lee J, Park S, Park H, Kim S, Lee J, Lee J, et al. Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell. 2019;177:1842-1857.e21 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:800; loading ...; fig 1f
| Yang W, Lee K, Srivastava R, Kuo F, Krishna C, Chowell D, et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat Med. 2019;25:767-775 pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 1c
| Middha S, Yaeger R, Shia J, Stadler Z, King S, Guercio S, et al. Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High. JCO Precis Oncol. 2019;3: pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 1c
| Gao X, Wu D, Dou L, Zhang H, Huang L, Zeng J, et al. Protective effects of mesenchymal stem cells overexpressing extracellular regulating kinase 1/2 against stroke in rats. Brain Res Bull. 2019;149:42-52 pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 1c
| Haney M, Klyachko N, Harrison E, Zhao Y, Kabanov A, Batrakova E. TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease. Adv Healthc Mater. 2019;8:e1801271 pubmed publisher |
- immunohistochemistry; human; 1:100; loading ...; fig 1c
| Genga R, Kernfeld E, Parsi K, Parsons T, Ziller M, Maehr R. Single-Cell RNA-Sequencing-Based CRISPRi Screening Resolves Molecular Drivers of Early Human Endoderm Development. Cell Rep. 2019;27:708-718.e10 pubmed publisher |
- mass cytometry; human; loading ...; fig 2j
- immunohistochemistry; human; loading ...; fig 6f
| Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher |
- western blot; human; loading ...; fig 1b
| Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher |
- immunohistochemistry - paraffin section; mouse; 1:200; fig s1c
- other; human; 1:40; loading ...; fig 2d
- western blot; human; 1:1000; loading ...; fig 5b
| Geng Y, Liu X, Liang J, Habiel D, Kulur V, Coelho A, et al. PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis. JCI Insight. 2019;4: pubmed publisher |
- immunocytochemistry; human; 1:50; fig 3a
| Po J, Ma Y, Balakrishna B, Brungs D, Azimi F, De Souza P, et al. Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status. PLoS ONE. 2019;14:e0211866 pubmed publisher |
- immunocytochemistry; human; 1:200; loading ...; fig 5a
- western blot; human; 1:1000; loading ...; fig 3b
| Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F, et al. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019;120:527-536 pubmed publisher |
- immunohistochemistry - paraffin section; human; 10 ug/ml; loading ...; fig s4
| Andre P, Denis C, Soulas C, Bourbon Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells. Cell. 2018;175:1731-1743.e13 pubmed publisher |
- western blot; human; loading ...; fig 1g
| Wu B, Sun X, Gupta H, Yuan B, Li J, Ge F, et al. Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. Oncoimmunology. 2018;7:e1500107 pubmed publisher |
- immunoprecipitation; human; 1:200; loading ...; fig 2b
- immunocytochemistry; human; 1:200; loading ...; fig 3e
| Cha J, Yang W, Xia W, Wei Y, Chan L, Lim S, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018;71:606-620.e7 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1
- western blot; human; 1:1000; loading ...; fig s6
| Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery. 2018;: pubmed publisher |
- western blot; human; loading ...; fig 6b
| Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:200; loading ...; fig 1a
| Zhu B, Tang L, Chen S, Yin C, Peng S, Li X, et al. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy. Oncogene. 2018;37:4941-4954 pubmed publisher |
- other; human; loading ...; fig 4c
| Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 5a
| Lin H, Wei S, Hurt E, Green M, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128:805-815 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 2a
- western blot; human; 1:2000; loading ...; fig 2a
| Parra E, Villalobos P, Mino B, Rodriguez Canales J. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol. 2018;26:83-93 pubmed publisher |
- immunohistochemistry; mouse; fig s4b
| Xu C, Zhang Y, Rolfe P, Hernández V, Guzman W, Kradjian G, et al. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. Clin Cancer Res. 2017;23:5869-5880 pubmed publisher |
- western blot; human; fig s5c
| Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77:3268-3279 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 3a
- western blot; human; 1:5000
| Guo M, Tomoshige K, Meister M, Muley T, Fukazawa T, Tsuchiya T, et al. Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med. 2017;9:462-481 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig s2b
| Buisseret L, Garaud S, de Wind A, Van den Eynden G, Boisson A, Solinas C, et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncoimmunology. 2017;6:e1257452 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:400; loading ...; fig 3c
| Sundara Y, Kostine M, Cleven A, Bovee J, Schilham M, Cleton Jansen A. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. Cancer Immunol Immunother. 2017;66:119-128 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:800; loading ...; fig 2c
| George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel A, et al. Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin Cancer Res. 2017;23:1220-1226 pubmed publisher |
- immunohistochemistry - paraffin section; human; fig 1a
| Kim W, Jung H, Nam S, Kim T, Heo D, Kim C, et al. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. Virchows Arch. 2016;469:581-590 pubmed |
- immunohistochemistry; human; 1:30; loading ...; fig s8c
| Li C, Lim S, Xia W, Lee H, Chan L, Kuo C, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...
| Gaule P, Smithy J, Toki M, Rehman J, Patell Socha F, Cougot D, et al. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncol. 2017;3:256-259 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 1
| Shi L, Fu T, Guan B, Chen J, Blando J, Allison J, et al. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined ?-CTLA-4+?-PD-1 therapy. Nat Commun. 2016;7:12335 pubmed publisher |
- western blot; human; 1:1000; fig 5e
| Zhang Y, Velez Delgado A, Mathew E, Li D, Mendez F, Flannagan K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut. 2017;66:124-136 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:100; fig 1
| Chen P, Roh W, Reuben A, Cooper Z, Spencer C, Prieto P, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016;6:827-37 pubmed publisher |
- immunohistochemistry - paraffin section; human; fig 1A
| Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE. 2016;11:e0153954 pubmed publisher |
- immunohistochemistry - frozen section; human
- western blot; human; fig 1
| Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139:396-403 pubmed publisher |
- immunohistochemistry; human; 1:500; fig s8
| Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed publisher |
- immunohistochemistry; human; 1:50; tbl 2
| Menter T, Dickenmann M, Juskevicius D, Steiger J, Dirnhofer S, Tzankov A. Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-κB signalling instead of B-cell receptor signalling. Hematol Oncol. 2017;35:187-197 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 2
| Feng Z, Puri S, Moudgil T, Wood W, Hoyt C, Wang C, et al. Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer. 2015;3:47 pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:500; loading ...; fig 1h
| Schmidt L, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch J, et al. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. PLoS ONE. 2015;10:e0136023 pubmed publisher |
| Kovaleva O, Rashidova M, Samoilova D, Podlesnaya P, Mochalnikova V, Gratchev A. Immunosuppressive Phenotype of Esophagus Tumors Stroma. Anal Cell Pathol (Amst). 2020;2020:5424780 pubmed publisher |
| Jiang G, Shi L, Zheng X, Zhang X, Wu K, Liu B, et al. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma. Aging (Albany NY). 2020;12:11466-11484 pubmed publisher |
| Cho I, Lee H, Yoon S, Ryu K, Ko Y, Kim W, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. BMC Cancer. 2020;20:120 pubmed publisher |
| Sudoyo A, Kurniawan A, Kusumo G, Putra T, Rexana F, Yunus M, et al. Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression. Asian Pac J Cancer Prev. 2019;20:3421-3427 pubmed publisher |
| Chandrasekaran D, Sundaram S, N K, R P. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma. Asian Pac J Cancer Prev. 2019;20:2951-2957 pubmed publisher |
| Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, et al. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?. Br J Cancer. 2019;121:278-280 pubmed publisher |
| Sato F, Ono T, Kawahara A, Kawaguchi T, Tanaka H, Shimamatsu K, et al. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol. 2019;: pubmed publisher |
| Guo C, Zhu Q, Tou F, Wen X, Kuang Y, Hu H. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma. BMC Cancer. 2019;19:289 pubmed publisher |
| Qiu L, Zheng H, Zhao X. The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis. BMC Cancer. 2019;19:273 pubmed publisher |
| Vitiello G, Bowler T, Liu M, Medina B, Zhang J, Param N, et al. Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. J Clin Invest. 2019;129:1863-1877 pubmed publisher |
| Kim S, Go S, Song D, Park S, Kim H, Jang I, et al. Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer. Br J Cancer. 2019;120:547-554 pubmed publisher |
| Kim R, Keam B, Kim S, Kim M, Kim S, Kim J, et al. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. BMC Cancer. 2019;19:19 pubmed publisher |
| Anastasiadou E, Stroopinsky D, Alimperti S, Jiao A, Pyzer A, Cippitelli C, et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2019;33:132-147 pubmed publisher |
| Wu X, Li Y, Liu X, Chen C, Harrington S, Cao S, et al. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon. 2018;4:e01039 pubmed publisher |
| Ma J, Li J, Qian M, Han W, Tian M, Li Z, et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N). Diagn Pathol. 2018;13:91 pubmed publisher |
| . 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018;6:114 pubmed publisher |
| Wang J, Xi Z, Xi J, Zhang H, Li J, Xia Y, et al. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing. Cancer Cell Int. 2018;18:159 pubmed publisher |
| Zou Y, Uddin M, Padmanabhan S, Zhu Y, Bu P, Vancura A, et al. The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells. J Biol Chem. 2018;293:15483-15496 pubmed publisher |
| Lin A, Jonsson P, Tabar V, Yang T, Cuaron J, Beal K, et al. Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. J Clin Endocrinol Metab. 2018;103:3925-3930 pubmed publisher |
| Lin J, Long J, Wan X, Chen J, Bai Y, Wang A, et al. Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. BMC Cancer. 2018;18:766 pubmed publisher |
| Dupuis F, Lamant L, Gerard E, Torossian N, Chaltiel L, Filleron T, et al. Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. Br J Cancer. 2018;119:193-199 pubmed publisher |
| Liu C, Xu J, Zhou Z, Jin L, Yu X, Xiao G, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer. 2018;119:80-88 pubmed publisher |
| Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, et al. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene. 2018;37:5257-5268 pubmed publisher |
| Hsu P, Miao J, Wang Y, Zhang W, Yang Y, Wang C, et al. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. J Cell Mol Med. 2018;22:3139-3148 pubmed publisher |
| Zamarin D, Ricca J, Sadekova S, Oseledchyk A, Yu Y, Blumenschein W, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128:1413-1428 pubmed publisher |
| Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13:12 pubmed publisher |
| Enninga E, Harrington S, Creedon D, Ruano R, Markovic S, Dong H, et al. Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy. Am J Reprod Immunol. 2017;: pubmed publisher |
| Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira N, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91-95 pubmed publisher |
| Seo A, Kang B, Kwon O, Park K, Lee S, Chung H, et al. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Br J Cancer. 2017;117:1753-1760 pubmed publisher |
| Yee D, Shah K, Coles M, Sharp T, Lagos D. MicroRNA-155 induction via TNF-? and IFN-? suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J Biol Chem. 2017;292:20683-20693 pubmed publisher |
| Kawakami F, Sircar K, Rodriguez Canales J, Fellman B, Urbauer D, Tamboli P, et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017;123:4823-4831 pubmed publisher |
| Mezzadra R, Sun C, Jae L, Gomez Eerland R, de Vries E, Wu W, et al. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature. 2017;549:106-110 pubmed publisher |
| Pelekanou V, Carvajal Hausdorf D, Altan M, Wasserman B, Carvajal Hausdorf C, Wimberly H, et al. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance. Breast Cancer Res. 2017;19:91 pubmed publisher |
| Pallett L, Davies J, Colbeck E, Robertson F, Hansi N, Easom N, et al. IL-2high tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J Exp Med. 2017;214:1567-1580 pubmed publisher |
| Lavin Y, Kobayashi S, Leader A, Amir E, Elefant N, Bigenwald C, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell. 2017;169:750-765.e17 pubmed publisher |
| Chevrier S, Levine J, Zanotelli V, Silina K, Schulz D, Bacac M, et al. An Immune Atlas of Clear Cell Renal Cell Carcinoma. Cell. 2017;169:736-749.e18 pubmed publisher |
| Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60-65 pubmed publisher |
| Motoshima T, Komohara Y, Ma C, Dewi A, Noguchi H, Yamada S, et al. PD-L1 expression in papillary renal cell carcinoma. BMC Urol. 2017;17:8 pubmed publisher |
| Kim J, Park H, Cho N, Lee H, Kang G. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer. 2016;115:490-6 pubmed publisher |
